Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Blower
P
P
Aapro
M
M
D000344:Afferent Pathways / Q000187:drug effects; D000932:Antiemetics / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000379:methods; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D017829:Granisetron / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D017294:Ondansetron / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects*; D044406:Receptors, Serotonin, 5-HT3; D012107:Research Design; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014630:Vagus Nerve / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control; D014840:Vomiting, Anticipatory / Q000523:psychology
D000932:Antiemetics; D000970:Antineoplastic Agents; D002945:Cisplatin; D017829:Granisetron; D017294:Ondansetron; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists